Skip to content

Whole Blood Specimen Collection From Healthy Subjects

Whole Blood Specimen Collection From Healthy Subjects

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02797743
Enrollment
750
Registered
2016-06-13
Start date
2015-07-31
Completion date
2021-09-30
Last updated
2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Healthy Volunteers

Brief summary

This study will obtain whole blood specimens from healthy subjects to be used for research and development and clinical validation of genetic assays.

Detailed description

Progenity is developing diagnostic products to improve the healthcare of men, women, and children. The commercial objective is to make safe, noninvasive genetic testing available to the public, independent of age and other factors that may contribute to pregnancy or other clinical complications. Sample specimens will not be used to develop genetic lines and/or DNA banks for cloning. Any samples or remnant specimens remaining may be stored indefinitely for future research programs. Eligible subjects (or parent/guardian) will provide written informed consent after which basic demographic and clinical data will be obtained and a whole blood sample will be collected. A subject's participation may end immediately after their blood draw. The amount of whole blood drawn at any visit will be based upon age of the subject and test to be performed. In the event a Subject is pregnant, information regarding the gender of the fetus established by either ultrasound, non-invasive prenatal testing (NIPT) results, or at delivery will be collected. Clinical data regarding any karyotyping procedure that may occur on the fetus will be recorded.

Interventions

* Adults ≥18 yrs of age: up to 50 mL (5 tubes) * Adolescents 12-17 yrs of age: up to 30 mL (3 tubes) * Children 0-11 yrs of age: single tube (1 tube, 10 mL)

Sponsors

Progenity, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Subject (or guardian)is willing to provide written informed consent to have up to 50 mL of whole blood collected at a single clinic visit (maximum blood volume will depend on age of subject) * Subject is considered healthy (and if pregnant, their pregnancy is progressing normally) * If pregnant, Subject is carrying a singleton fetus of 10 to 26 weeks' gestational age inclusive

Exclusion criteria

* Women who are not pregnant * If pregnant, pregnancy is non-viable * If pregnant, evidence of or suspected fetal anomaly based on ultrasound finding, abnormal 1st trimester screening or abnormal NIPT * Immediate family history of a previous fetal aneuploidy

Design outcomes

Primary

MeasureTime frameDescription
Whole blood collectionabout 3 yearsWhole blood collection from 750 healthy subjects total

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026